Alnylam Pharmaceuticals, Inc. (ALNY)
NASDAQ: ALNY · IEX Real-Time Price · USD
247.61
+4.29 (1.76%)
At close: Jul 2, 2024, 4:00 PM
248.00
+0.39 (0.16%)
After-hours: Jul 2, 2024, 6:21 PM EDT
Alnylam Pharmaceuticals Stock Forecast
Stock Price Forecast
The 19 analysts with 12-month price forecasts for ALNY stock have an average target of 250.74, with a low estimate of 150 and a high estimate of 400. The average target predicts an increase of 1.26% from the current stock price of 247.61.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for ALNY stock from 21 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Feb '24 | Mar '24 | Apr '24 | May '24 | Jun '24 | Jul '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 5 | 5 | 5 | 8 | 8 |
| Buy | 5 | 4 | 4 | 4 | 6 | 6 |
| Hold | 8 | 8 | 8 | 7 | 7 | 7 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 20 | 17 | 17 | 16 | 21 | 21 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Cantor Fitzgerald | Cantor Fitzgerald | Hold Reiterates $150 | Hold | Reiterates | $150 | -39.42% | Jul 1, 2024 |
| UBS | UBS | Strong Buy Maintains $253 → $288 | Strong Buy | Maintains | $253 → $288 | +16.31% | Jun 28, 2024 |
| RBC Capital | RBC Capital | Buy Maintains $250 → $265 | Buy | Maintains | $250 → $265 | +7.02% | Jun 27, 2024 |
| Stifel | Stifel | Strong Buy Maintains $215 → $295 | Strong Buy | Maintains | $215 → $295 | +19.14% | Jun 27, 2024 |
| Citigroup | Citigroup | Strong Buy Maintains $227 → $291 | Strong Buy | Maintains | $227 → $291 | +17.52% | Jun 25, 2024 |
Financial Forecast
Revenue This Year
1.91B
from 1.83B
Increased by 4.69%
Revenue Next Year
2.33B
from 1.91B
Increased by 21.47%
EPS This Year
-3.54
from -3.52
EPS Next Year
-1.90
from -3.54
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 2.1B | 3.1B | 4.8B | 6.8B | 8.6B |
| Avg | 1.9B | 2.3B | 3.1B | 3.9B | 4.9B |
| Low | 1.7B | 1.5B | 1.8B | 2.8B | 3.1B |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 14.8% | 63.2% | 104.8% | 122.1% | 122.9% |
| Avg | 4.7% | 21.5% | 31.8% | 25.9% | 26.7% |
| Low | -7.2% | -24.2% | -22.5% | -9.8% | -19.6% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -1.12 | 2.43 | 9.66 | 22.21 | 26.03 |
| Avg | -3.54 | -1.90 | 2.02 | 8.04 | 12.70 |
| Low | -5.45 | -4.29 | -2.75 | 3.11 | 7.05 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | 1,000.3% | 223.7% |
| Avg | - | - | - | 298.3% | 57.9% |
| Low | - | - | - | 53.9% | -12.4% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.